Current Topics on Prostate Cancer Treatment : 23rd SIU Congress, Sydney, September 1994. Supplement Issue: Urologia Internationalis 1996, Vol. 56, Suppl. 1
Opening with a critical assessment of the controversies that abound in relation to the treatment of every stage of prostate cancer, this publication focuses on the evaluation of new pharmacological developments in prostates cancer treatment. The first study investigates the effects of neoadjuvant androgen-ablative therapy (NAT) in a large patient population who all underwent radical prostatectomy. It attempts to answer the question of whether NAT can influence the definitive tumor pathology stage. The following studies compare the effectiveness of total androgen withdrawal with medical testicular suppression in advanced prostatic cancer and assess the clinical efficacy of a new 3-month depot of gonadotrophin-releasing hormone analogues as compared to a 1-month depot. The latter study illustrates good tolerance with the same level of testosterone suppression. Finally, preliminary results of long-term follow-up study of leuprorelin acetate depot (LAD) are presented which indicate that LAD is an effective treatment for advanced prostatic cancer.
- Paperback | 28 pages
- 209.55 x 279.4 x 6.35mm | 155g
- 01 Apr 1996
- S Karger Ag
- Basel, Switzerland
- 15 fig., 15 tab.
Table of contents
Issues on early diagnosis and treatment of localized prostate cancer, J.E. Pontes; effects of androgen deprivation prior to radical prostatectomy in 375 patients, U.W. Tumn et al; combination treatment versus LHRH alone in advanced prostatic cancer, P. Ferrari et al; clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostatic carcinoma, P. Fornara and D. Jocham; efficacy and safety of leuprorelin acetate depot for prostate cancer in a long-term follow-up study - preliminary results, E. Kienle et al.